P436 Malignancies in children receiving infliximab and other inflammatory bowel disease therapies: an inflammatory bowel disease multicenter, prospective, long-term registry of pediatric patients (DEVELOP) registry data
Richard B. Colletti(Greenville College), Gigi Veereman, M Dubinsky, Johanna C. Escher(Erasmus MC - Sophia Children’s Hospital), Jeffrey Hyams(Herlev Hospital), Salvatore Cucchiara(Massachusetts General Hospital), Sibylle Koletzko(LMU Klinikum), Anne M. Griffiths(University of Toronto), Harland S. Winter(Massachusetts General Hospital), Linda Tang, James Markowitz(Philadelphia University), P. Callegari, R Baldassano(Herlev Hospital), R Wright(University Hospital Complex Of Vigo), Mark R. Molenda, F. Ruemmele, B. Gold, Subra Kugathasan(Children's Healthcare of Atlanta), J. M. Fell(Chelsea and Westminster Hospital NHS Foundation Trust), William A. Faubion(Mayo Clinic in Arizona)
Cited by 3
Related Papers
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k